DSIP (Emideltide): Evidence, Legal Status, and Safety
DSIP (delta sleep-inducing peptide, drug name Emideltide) has more old human trial data than most research peptides, but those trials are 40+ years old, small, and unreplicated. On 24 Jul 2026, it was the one peptide of seven an FDA advisory committee reviewed that it recommended against. It has no legal path to human use today.
Understand what's actually being sold A synthetic nonapeptide studied since the 1970s and 80s for a proposed effect on deep, delta-wave sleep; reviewed by the FDA in 2026 under the drug name Emideltide.
"DSIP" (the popular research-chemical name) and "Emideltide" (the name in the FDA's review) refer to the same molecule.
See what the human evidence actually is Several small double-blind human trials from the 1980s and 90s (largest n=16) reported improved sleep measures versus placebo. All are 40+ years old and have not been replicated at modern trial standards; none tested the opioid-withdrawal claim it is also marketed for.
Old, small, unreplicated human trials are real evidence, more than most peptides in this category have, but they do not meet a modern evidentiary bar, and the sleep evidence does not extend to the withdrawal claim.
Know where it actually stands Not FDA-approved for any human use; sold as an unregulated research chemical. On 24 Jul 2026 the FDA's Pharmacy Compounding Advisory Committee reviewed DSIP (as Emideltide) and recommended against adding it to the compounding list, the only rejection among the seven peptides reviewed that week.
DSIP is the one peptide in this set that its own advisory committee declined to recommend, which puts it further from legal access than the other six.
Know the real risk The 1980s and 90s trials reported no significant adverse events at studied doses, but that is not the same as a modern safety review. Standard unregulated-sourcing risk applies to any product sold today.
An absence of reported side effects in four small, decades-old trials is not a current safety guarantee for an unregulated product.
DSIP has the oldest, and in raw trial count the most, human data of any peptide in this report: a double-blind crossover study in 6 normal volunteers (PMID 6895513) found increased total sleep time in a post-dose window versus placebo; intravenous DSIP in 6 middle-aged chronic insomniacs (PMID 7028502) produced longer, higher-quality sleep with no reported daytime sedation; a double-blind study in 16 chronic insomniac patients (PMID 1299794) found higher sleep efficiency and shorter sleep latency versus placebo; and an open study of 7 patients with severe insomnia (PMID 6391926) reported sleep normalized for 3 to 7 months in 6 of 7 cases.
View sources
Delta sleep-inducing peptide (DSIP) crossover trial in normal volunteers
Intravenous DSIP in chronic insomniacs
Double-blind DSIP study in chronic insomniac patients
Open study of DSIP in severe insomnia
Not medical advice. This page is for education only and is not a substitute for professional medical care. Consult a qualified clinician before changing your health routine.
Editorial disclosure. This protocol is written and fact-checked by the YourProtocol editorial team directly from the primary sources cited below; it is not written or reviewed by any outside expert.
Is this for you
- Anyone considering DSIP/Emideltide who wants the honest evidence before discussing it with a clinician
- Readers who have seen it marketed for opioid withdrawal and want to know that claim is not the one with trial support
- Readers comparing DSIP to the site's evidence-graded sleep stack
Cautions
- Not FDA-approved for any human use; sold as an unregulated research chemical with no purity or sterility guarantee.
- The FDA's advisory committee recommended against DSIP (as Emideltide) on 24 Jul 2026, the only rejection among seven peptides reviewed that week; it has no pending legal pathway.
- The sleep trials cited here are 40+ years old, small, and unreplicated; they say nothing about the opioid-withdrawal claim it is also marketed for.
- Educational only, not medical advice.